Glucagon · source year
2 selected, source-linked Glucagon records carrying a 2021 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
2 selected records.
2 represented types.
2 distinct public records.
Cited chronology
Regulatory
The Federal Register published notice 2021-24431, attributed to FDA and its parent HHS department, on 2021-11-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Leuprolide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04347252 at 2026-07-30T20:03:05.484Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗